PharmaLeaders.com

News. Resources. Community.

  • Features
  • Channels
    • Biotech Channel
    • Clinical Channel
    • CME Channel
    • Compliance Channel
    • Device Channel
    • HIMSS Channel
    • Marketing Channel
    • Pharma Channel
    • R&D Channel
    • Telehealth Channel
    • Training Channel
  • Events
  • On Demand
  • White Papers
  • Vendors
    • Biotech Vendors
    • Clinical Vendors
    • CME Vendors
    • Compliance Vendors
    • Device Vendors
    • Marketing Vendors
    • Pharma Vendors
    • R&D Vendors
    • Training Vendors
  • Contributors

CHMP recommends AstraZeneca’s Tezspire for approval to treat severe asthma

08/05/2022 by PharmaLeaders Aggregator

This post was originally published on this site

Tezspire has been recommended as an add-on therapy for these patients whose condition is not sufficiently controlled with high dose inhaled corticosteroids besides another medicinal product for maintenance

The post CHMP recommends AstraZeneca’s Tezspire for approval to treat severe asthma appeared first on Pharmaceutical Business review.

Filed Under: Industry News

  • Facebook
  • LinkedIn
  • Twitter

Choose Your Channel

Receive event announcements and special reports directly in your inbox.
  • This field is for validation purposes and should be left unchanged.

Upcoming Events

  1. Reuters Events: Cell & Gene Therapy USA 2022

    September 20 - September 21
  2. Indegene Digital Summit 2022

    September 22 - September 23
  3. 3rd Clinical Trial Agreements Forum

    September 29 - September 30
  4. 2nd Omnichannel Marketing Strategy Symposium

    September 29 - September 30
  5. Oncology at Total Health 2022

    October 20 - October 21

View All Events

  • About Us
  • Sponsorship
  • Join Our Team
  • Contact Us

Copyright © 2022 PharmaLeaders.com. All rights reserved.

Copyright © 2022 · Magazine Pro Theme on Genesis Framework · WordPress · Log in